Template:ACLS Wide Regular Tachycardia - Revision history

Ostermayer at 02:02, 18 January 2026

2026-01-18T02:02:55Z

← Older revision		Revision as of 02:02, 18 January 2026
Line 1:		Line 1:
	<languages/>		<noinclude><languages/></noinclude>
	<translate>		<translate>

Ostermayer: Prepared the page for translation

2026-01-18T02:02:27Z

Prepared the page for translation

← Older revision		Revision as of 02:02, 18 January 2026
Line 1:		Line 1:
	===[[Wide-complex tachycardia\|Wide ''Regular'' Tachycardia]]<ref>American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org</ref>===		<languages/>
	[[File:Lead II rhythm ventricular tachycardia Vtach VT.jpg\|thumb\|Wide ''Regular'' Tachycardia (consistent with [[ventricular tachycardia]]).]]		<translate>
	''Pulseless: see [[Adult pulseless arrest]]''
			===[[Special:MyLanguage/Wide-complex tachycardia\|Wide ''Regular'' Tachycardia]]<ref>American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org</ref>===

			[[File:Lead II rhythm ventricular tachycardia Vtach VT.jpg\|thumb\|Wide ''Regular'' Tachycardia (consistent with [[Special:MyLanguage/ventricular tachycardia\|ventricular tachycardia]]).]]
			''Pulseless: see [[Special:MyLanguage/Adult pulseless arrest\|Adult pulseless arrest]]''
	*'''Unstable''': Hypotension, altered mental status, shock, ischemic chest discomfort, acute heart failure		*'''Unstable''': Hypotension, altered mental status, shock, ischemic chest discomfort, acute heart failure
	**[[Synchronized cardioversion]] 100-200J		**[[Special:MyLanguage/Synchronized cardioversion\|Synchronized cardioversion]] 100-200J
	*'''Stable''':		*'''Stable''':
	*Medications		*Medications
	**[[Procainamide]] (first-line drug of choice)		**[[Special:MyLanguage/Procainamide\|Procainamide]] (first-line drug of choice)
	***20-50 mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr		***20-50 mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr
	****Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>		****Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>
	***Stop if QRS duration increases >50% or [[hypotension]]		***Stop if QRS duration increases >50% or [[Special:MyLanguage/hypotension\|hypotension]]
	***Avoid if [[prolonged QT]] or [[CHF]]		***Avoid if [[Special:MyLanguage/prolonged QT\|prolonged QT]] or [[Special:MyLanguage/CHF\|CHF]]
	***Favored over Amiodarone in PROCAMIO trial; termination of tachycardia in 67% of procainamide group vs 38% of amiodarone group, adverse cardiac events 9% vs 41%, respectively <ref>Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 May 1;38(17):1329-1335</ref>		***Favored over Amiodarone in PROCAMIO trial; termination of tachycardia in 67% of procainamide group vs 38% of amiodarone group, adverse cardiac events 9% vs 41%, respectively <ref>Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 May 1;38(17):1329-1335</ref>
	**[[Amiodarone]] (agent of choice in setting of [[AMI]] or LV dysfunction)		**[[Special:MyLanguage/Amiodarone\|Amiodarone]] (agent of choice in setting of [[Special:MyLanguage/AMI\|AMI]] or LV dysfunction)
	***150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>		***150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>
	***Then 0.5 mg/min drip over next 18 hrs (540 mg total)		***Then 0.5 mg/min drip over next 18 hrs (540 mg total)
	***Oral dosage after IV infusion is 400 -800 mg PO daily		***Oral dosage after IV infusion is 400 -800 mg PO daily
	**Consider [[adenosine]]		**Consider [[Special:MyLanguage/adenosine\|adenosine]]
	***Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])		***Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[Special:MyLanguage/rhythm diagnosis in regular wide complex tachycardia\|rhythm diagnosis in regular wide complex tachycardia]])
	***6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push		***6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push
	**Synchronized [[cardioversion]] (100J)		**Synchronized [[Special:MyLanguage/cardioversion\|cardioversion]] (100J)
			</translate>

Rossdonaldson1: /* Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org */

2025-07-30T16:54:06Z

Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org

← Older revision		Revision as of 16:54, 30 July 2025
Line 1:		Line 1:
	===[[Wide-complex tachycardia\|Wide ''Regular'' Tachycardia]]<ref>American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org</ref>===		===[[Wide-complex tachycardia\|Wide ''Regular'' Tachycardia]]<ref>American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org</ref>===
	[[File:Lead II rhythm ventricular tachycardia Vtach VT.jpg\|thumb\|Wide ''Regular'' Tachycardia (consistent with [[ventricular tachycardia]])).]]		[[File:Lead II rhythm ventricular tachycardia Vtach VT.jpg\|thumb\|Wide ''Regular'' Tachycardia (consistent with [[ventricular tachycardia]]).]]
	''Pulseless: see [[Adult pulseless arrest]]''		''Pulseless: see [[Adult pulseless arrest]]''
	*'''Unstable''': Hypotension, altered mental status, shock, ischemic chest discomfort, acute heart failure		*'''Unstable''': Hypotension, altered mental status, shock, ischemic chest discomfort, acute heart failure

Rossdonaldson1: /* Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org */

2025-07-30T16:53:46Z

← Older revision		Revision as of 16:53, 30 July 2025
Line 1:		Line 1:
	===[[Wide-complex tachycardia\|Wide ''Regular'' Tachycardia]]<ref>American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org</ref>===		===[[Wide-complex tachycardia\|Wide ''Regular'' Tachycardia]]<ref>American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org</ref>===
			[[File:Lead II rhythm ventricular tachycardia Vtach VT.jpg\|thumb\|Wide ''Regular'' Tachycardia (consistent with [[ventricular tachycardia]])).]]
	''Pulseless: see [[Adult pulseless arrest]]''		''Pulseless: see [[Adult pulseless arrest]]''
	*'''Unstable''': Hypotension, altered mental status, shock, ischemic chest discomfort, acute heart failure		*'''Unstable''': Hypotension, altered mental status, shock, ischemic chest discomfort, acute heart failure

Rossdonaldson1: /* Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org */

2025-07-30T16:39:33Z

← Older revision		Revision as of 16:39, 30 July 2025
Line 6:		Line 6:
	*Medications		*Medications
	**[[Procainamide]] (first-line drug of choice)		**[[Procainamide]] (first-line drug of choice)
	***20-~~50mg~~/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr		***20-50 mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr
	****Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>		****Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>
	***Stop if QRS duration increases >50% or [[hypotension]]		***Stop if QRS duration increases >50% or [[hypotension]]

Rossdonaldson1: /* Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org */

2025-07-30T16:38:07Z

← Older revision		Revision as of 16:38, 30 July 2025
Line 18:		Line 18:
	***Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])		***Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])
	***6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push		***6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push
	**Synchronized [[~~Cardioversion~~]] (100J)		**Synchronized [[cardioversion]] (100J)

Cdichang: /* Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org */

2022-12-03T21:50:50Z

← Older revision		Revision as of 21:50, 3 December 2022
Line 18:		Line 18:
	***Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])		***Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])
	***6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push		***6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push
	*Synchronized [[Cardioversion]] (100J)		**Synchronized [[Cardioversion]] (100J)

Rossdonaldson1: /* Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org */

2019-04-05T04:40:57Z

← Older revision		Revision as of 04:40, 5 April 2019
Line 1:		Line 1:
	===[[Wide complex tachycardia\|Wide ''Regular'' Tachycardia]]<ref>American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org</ref>===		===[[Wide-complex tachycardia\|Wide ''Regular'' Tachycardia]]<ref>American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org</ref>===
	''Pulseless: see [[Adult pulseless arrest]]''		''Pulseless: see [[Adult pulseless arrest]]''
	*'''Unstable''': Hypotension, altered mental status, shock, ischemic chest discomfort, acute heart failure		*'''Unstable''': Hypotension, altered mental status, shock, ischemic chest discomfort, acute heart failure

SLuckettG: /* Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org */

2019-03-18T20:20:30Z

Rossdonaldson1: /* Wide Regular TachycardiaAmerican Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7: Adult Advanced Cardiovascular Life Support. ECCguidelines.heart.org */

2018-03-14T12:10:32Z

← Older revision		Revision as of 12:10, 14 March 2018
Line 5:		Line 5:
	*'''Stable''':		*'''Stable''':
	*#Medications		*#Medications
	#[[Procainamide]] (first line drug of choice)		#[[Procainamide]] (first-line drug of choice)
	#*20-50mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr		#*20-50mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr
	#**Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>		#**Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>
Line 11:		Line 11:
	#*Avoid if [[prolonged QT]] or [[CHF]]		#*Avoid if [[prolonged QT]] or [[CHF]]
	#*Favored over Amiodarone in PROCAMIO trial; termination of tachycardia in 67% of procainamide group vs 38% of amiodarone group, adverse cardiac events 9% vs 41%, respectively <ref>Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 May 1;38(17):1329-1335</ref>		#*Favored over Amiodarone in PROCAMIO trial; termination of tachycardia in 67% of procainamide group vs 38% of amiodarone group, adverse cardiac events 9% vs 41%, respectively <ref>Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 May 1;38(17):1329-1335</ref>
	#[[Amiodarone]], agent of choice in setting of AMI or LV dysfunction		#[[Amiodarone]] (agent of choice in setting of [[AMI]] or LV dysfunction)
	#*150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>		#*150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>
	#*Then 0.5 mg/min drip over next 18 hrs (540 mg total)		#*Then 0.5 mg/min drip over next 18 hrs (540 mg total)
	#*Oral dosage after IV infusion is 400 -800 mg PO daily		#*Oral dosage after IV infusion is 400 -800 mg PO daily
	#[[~~Adenosine~~]]		#Consider [[adenosine]]
	#*~~May be considered~~ for diagnosis and treatment ~~only~~ if rhythm is regular and monomorphic		#*Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])
	#*6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push		#*6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push
	*#Synchronized [[Cardioversion]] (100J)		*#Synchronized [[Cardioversion]] (100J)

← Older revision		Revision as of 12:10, 14 March 2018
Line 5:		Line 5:
	*'''Stable''':		*'''Stable''':
	*#Medications		*#Medications
	#[[Procainamide]] (first line drug of choice)		#[[Procainamide]] (first-line drug of choice)
	#*20-50mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr		#*20-50mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr
	#**Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>		#**Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>
Line 11:		Line 11:
	#*Avoid if [[prolonged QT]] or [[CHF]]		#*Avoid if [[prolonged QT]] or [[CHF]]
	#*Favored over Amiodarone in PROCAMIO trial; termination of tachycardia in 67% of procainamide group vs 38% of amiodarone group, adverse cardiac events 9% vs 41%, respectively <ref>Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 May 1;38(17):1329-1335</ref>		#*Favored over Amiodarone in PROCAMIO trial; termination of tachycardia in 67% of procainamide group vs 38% of amiodarone group, adverse cardiac events 9% vs 41%, respectively <ref>Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 May 1;38(17):1329-1335</ref>
	#[[Amiodarone]], agent of choice in setting of AMI or LV dysfunction		#[[Amiodarone]] (agent of choice in setting of [[AMI]] or LV dysfunction)
	#*150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>		#*150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>
	#*Then 0.5 mg/min drip over next 18 hrs (540 mg total)		#*Then 0.5 mg/min drip over next 18 hrs (540 mg total)
	#*Oral dosage after IV infusion is 400 -800 mg PO daily		#*Oral dosage after IV infusion is 400 -800 mg PO daily
	#[[~~Adenosine~~]]		#Consider [[adenosine]]
	#*~~May be considered~~ for diagnosis and treatment ~~only~~ if rhythm is regular and monomorphic		#*Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])
	#*6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push		#*6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push
	*#Synchronized [[Cardioversion]] (100J)		*#Synchronized [[Cardioversion]] (100J)

← Older revision		Revision as of 20:20, 18 March 2019
Line 4:		Line 4:
	**[[Synchronized cardioversion]] 100-200J		**[[Synchronized cardioversion]] 100-200J
	*'''Stable''':		*'''Stable''':
	*#Medications		*Medications
	#[[Procainamide]] (first-line drug of choice)		**[[Procainamide]] (first-line drug of choice)
	#*20-50mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr		***20-50mg/min until arrhythmia suppressed (max 17mg/kg or 1 gram); then, maintenance infusion of 1-4mg/min x 6hr
	#**Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>		****Alternative administration: 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>
	#*Stop if QRS duration increases >50% or [[hypotension]]		***Stop if QRS duration increases >50% or [[hypotension]]
	#*Avoid if [[prolonged QT]] or [[CHF]]		***Avoid if [[prolonged QT]] or [[CHF]]
	#*Favored over Amiodarone in PROCAMIO trial; termination of tachycardia in 67% of procainamide group vs 38% of amiodarone group, adverse cardiac events 9% vs 41%, respectively <ref>Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 May 1;38(17):1329-1335</ref>		***Favored over Amiodarone in PROCAMIO trial; termination of tachycardia in 67% of procainamide group vs 38% of amiodarone group, adverse cardiac events 9% vs 41%, respectively <ref>Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 May 1;38(17):1329-1335</ref>
	#[[Amiodarone]] (agent of choice in setting of [[AMI]] or LV dysfunction)		**[[Amiodarone]] (agent of choice in setting of [[AMI]] or LV dysfunction)
	#*150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>		***150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>
	#*Then 0.5 mg/min drip over next 18 hrs (540 mg total)		***Then 0.5 mg/min drip over next 18 hrs (540 mg total)
	#*Oral dosage after IV infusion is 400 -800 mg PO daily		***Oral dosage after IV infusion is 400 -800 mg PO daily
	#Consider [[adenosine]]		**Consider [[adenosine]]
	#*Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])		***Consider for diagnosis and treatment, if rhythm is regular and monomorphic (see [[rhythm diagnosis in regular wide complex tachycardia]])
	#*6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push		***6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push
	*#Synchronized [[Cardioversion]] (100J)		*Synchronized [[Cardioversion]] (100J)